MCF.2 cell line derived transforming sequence-like (MCF2L)

MCF.2 cell line derived transforming sequence-like (MCF2L) encodes a guanine nucleotide exchange factor (GEF) that activates Rho family small GTPases—primarily RhoA and CDC42—regulating Rho/Rac signaling pathways[1][2][3][6]. It contains a pleckstrin homology domain and is involved in modulating cytoskeletal dynamics, cell migration, and signal transduction. Genetic variants in MCF2L are significantly associated with osteoarthritis susceptibility and have been implicated in cardiovascular pathologies and cancer progression by affecting the activation of Rho GTPases and influencing cell survival and proliferation[1][2][3]. Aberrant expression or variants of MCF2L can impair cytoskeletal organization, with altered expression noted in some chemoresistant cancer cells, indicating further roles in modulating cell fate decisions and potentially therapy response[1][7][3]. Multiple transcript variants and protein isoforms exist, including an N-terminal truncated form that is highly tumorigenic[2][3]. Other commonly used names for this protein include ARHGEF14, DBS, OST, and DBL’s big sister[1][2][3][4][6]. No interacting drugs, mechanisms of drug action, or notable safety concerns are reported in current publicly available data. MCF2L is recognized as a relevant target in signal transduction and pathogenesis of major diseases, especially in settings of joint, vascular, and neoplastic disorders[1][2][3][6].

Other names

ARHGEF14DBSOSTguanine nucleotide exchange factor DBSDBL's big sisterMCF2 transforming sequence-like proteinKIAA0362